行情

GERN

GERN

杰龙
NASDAQ

实时行情|Nasdaq Last Sale

1.380
+0.020
+1.47%
盘后: 1.380 0 0.00% 16:00 09/21 EDT
开盘
1.380
昨收
1.360
最高
1.400
最低
1.340
成交量
178.90万
成交额
--
52周最高
2.355
52周最低
1.200
市值
4.42亿
市盈率(TTM)
-4.4146
分时
5日
1月
3月
1年
5年
简报-Geron 报告根据纳斯达克上市规则 5635(C)(4) 的诱导授予
reuters.com · 5天前
Geron 根据纳斯达克上市规则 5635(c)(4) 报告诱导补助金
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 400,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with ...
Business Wire · 5天前
Geron 宣布 9 月投资者大会演示网络广播
FOSTER CITY, Calif., September 01, 2021--Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:
Business Wire · 09/01 20:30
Geron 根据纳斯达克上市规则 5635(c)(4) 报告诱导性赠款
FOSTER CITY, Calif., August 19, 2021--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 550,000 shares of Geron common stock as inducements to newly hired employees in connection wit...
Business Wire · 08/19 20:30
The Daily Biotech Pulse:礼来重组神经科学业务部门,Helius Medical 获得突破性指定,Ra Medical 出售皮肤科业务
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Geron (GERN) 报告第二季度亏损,高于收入预期
Geron (GERN) delivered earnings and revenue surprises of 0.00% and 33.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/16 21:25
简报-Geron 公司报告称,Imerge 阶段 3 的注册人数超过 90%,预计顶线结果将加速到 2023 年第一季度
reuters.com · 08/16 21:09
回顾:Geron Q2 收益
Shares of Geron (NASDAQ:GERN) rose 2.5% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 50.00% over the past year to ($0.09), which missed the estimate of ($0.08).
Benzinga · 08/16 20:45
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解GERN最新的财务预测,通过GERN每股收益,每股净资产,每股现金流等数据分析杰龙近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测GERN价格均价为4.200,最高价位7.00,最低价为3.000。
EPS
机构持股
总机构数: 200
机构持股: 1.33亿
持股比例: 41.40%
总股本: 3.21亿
类型机构数股数
增持
42
216.39万
建仓
20
103.02万
减持
43
1,090.75万
平仓
21
601.75万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.32%
制药与医学研究
+0.74%
高管信息
Chairman/President/Chief Executive Officer/Director
John Scarlett
Chief Financial Officer/Executive Vice President - Finance/Treasurer
Olivia Bloom
Chief Operating Officer/Executive Vice President
Andrew Grethlein
Executive Vice President/Secretary
Stephen Rosenfield
Executive Vice President
Anil Kapur
Executive Vice President
Melissa Kelly Behrs
Executive Vice President
Aleksandra Rizo
Lead Director/Independent Director
Karin Eastham
Independent Director
Dawn Bir
Independent Director
V. Bryan Lawlis
Independent Director
Susan Molineaux
Independent Director
Elizabeth O'Farrell
Independent Director
Robert Spiegel
暂无数据
GERN 简况
Geron Corp(Geron)是一家后期临床生物制药公司,专注于imetelstat(血液性骨髓恶性肿瘤的治疗药物)的开发和商业化。该公司运营一个业务部门,该部门从事肿瘤治疗产品的开发业务。imetelstat是一种脂质共轭13-mer寡核苷酸,旨在与端粒酶的核糖核酸(RNA)模板互补并以高亲和力结合,从而直接抑制端粒酶活性。imetelstat的临床研究包括IMerge(低风险骨髓增生异常综合症(MDS)的II/III期试验)和IMbark(中度II或高危骨髓纤维化的II期试验)。

微牛提供Geron Corporation(NASDAQ-GERN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的GERN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GERN股票基本功能。